These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31216704)

  • 1. Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation.
    Fischer T; Riedl R
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31216704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Structural Evolution of Matrix Metalloproteinase Inhibitors.
    Fischer T; Senn N; Riedl R
    Chemistry; 2019 Jun; 25(34):7960-7980. PubMed ID: 30720221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.
    Fabre B; Ramos A; de Pascual-Teresa B
    J Med Chem; 2014 Dec; 57(24):10205-19. PubMed ID: 25265401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study.
    Singh T; Adekoya OA; Jayaram B
    Mol Biosyst; 2015 Apr; 11(4):1041-51. PubMed ID: 25611160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational Approaches to Matrix Metalloprotease Drug Design.
    Singh T; Jayaram B; Adekoya OA
    Methods Mol Biol; 2017; 1579():273-285. PubMed ID: 28299743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.
    Arkadash V; Yosef G; Shirian J; Cohen I; Horev Y; Grossman M; Sagi I; Radisky ES; Shifman JM; Papo N
    J Biol Chem; 2017 Feb; 292(8):3481-3495. PubMed ID: 28087697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs.
    Jain M; Harburn JJ; Gill JH; Loadman PM; Falconer RA; Mooney CA; Cobb SL; Berry DJ
    J Med Chem; 2017 May; 60(10):4496-4502. PubMed ID: 28471664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
    El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
    Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
    Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
    Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies against metzincin targets.
    Santamaria S; de Groot R
    Br J Pharmacol; 2019 Jan; 176(1):52-66. PubMed ID: 29488211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles.
    Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S
    Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF
    Erdeljac N; Thiehoff C; Jumde RP; Daniliuc CG; Höppner S; Faust A; Hirsch AKH; Gilmour R
    J Med Chem; 2020 Jun; 63(11):6225-6237. PubMed ID: 32379447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined structure- and ligand-based pharmacophore modeling and molecular dynamics simulation studies to identify selective inhibitors of MMP-8.
    Kalva S; Vinod D; Saleena LM
    J Mol Model; 2014 May; 20(5):2191. PubMed ID: 24756550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains.
    Chen IJ; Chuang CH; Hsieh YC; Lu YC; Lin WW; Huang CC; Cheng TC; Cheng YA; Cheng KW; Wang YT; Chen FM; Cheng TL; Tzou SC
    Sci Rep; 2017 Sep; 7(1):11587. PubMed ID: 28912497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Broad-Spectrum MMP Inhibitors by Virtual Screening.
    Gimeno A; Cuffaro D; Nuti E; Ojeda-Montes MJ; Beltrán-Debón R; Mulero M; Rossello A; Pujadas G; Garcia-Vallvé S
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.
    Fields GB
    Front Immunol; 2019; 10():1278. PubMed ID: 31214203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases.
    Amar S; Minond D; Fields GB
    Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 28613012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
    Rashid ZA; Bardaweel SK
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific interactions between zinc metalloproteinase and its inhibitors: Ab initio fragment molecular orbital calculations.
    Ara A; Kadoya R; Ishimura H; Shimamura K; Sylte I; Kurita N
    J Mol Graph Model; 2017 Aug; 75():277-286. PubMed ID: 28618335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.